Company profile
Home - Epsilogen
Epsilogen Ltd is a UK company with status active founded in 2016.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQzNDk1NTExN2FkaXF6a2N4
Published 10 Sep 2024 09:25
SH01 | Transaction MzQzNDgwMTc5NmFkaXF6a2N4
Published 06 Sep 2024 17:23
SH01 | Transaction MzQzNDUxMDQwNWFkaXF6a2N4
Published 05 Sep 2024 09:06
SH01 | Transaction MzQzNDQ5NzgxOWFkaXF6a2N4
Published 04 Sep 2024 13:53
CS01 | Transaction MzQzMTg1MzY0OGFkaXF6a2N4
Published 12 Aug 2024 13:06
PSC07 | Transaction MzQzMTcxMDQxN2FkaXF6a2N4
Published 09 Aug 2024 10:24
PSC08 | Transaction MzQzMTcxMDQxOGFkaXF6a2N4
Published 09 Aug 2024 10:24
PSC07 | Transaction MzQzMTcxMDQxNmFkaXF6a2N4
Published 09 Aug 2024 10:24
Company registered at Companies House
Epsilogen develops drugs for use in immuno-oncology, specifically antibodies that can target and destroy solid tumours.
Epsilogen Ltd. is developing a novel antibody platform technology based on engineering of the epsilon constant region.
1 Oct 2020 to 31 Dec 2022
Epsilogen (formerly IGEM Therapeutics) is developing a novel HER2-targeted antibody EPS 201, selected on a number of key attributes that sets it apart from marketed competitors. The project seeks to move EPS 201 closer to the clinic through development of product quality assays, _in vivo_ models for GLP toxicology and efficacy, and a manufacturing cell li...
1 May 2020 to 31 Oct 2021
IGEM Therapeutics Ltd aims to develop new platform technologies for creating therapeutic IgE molecules with enhanced anti-tumour activities. The Fc region of IgE has been engineered to introduce additional functionality with a view to improving anti-tumour responses, in particular for treatment of solid tumours. An immediate output of the project will be ...
1 Jan 2019 to 30 Nov 2020
IGEM Therapeutics Ltd aims to develop a novel HER2-targeted antibody that will address a number of unmet clinical needs. It will exploit innovative animal models, novel HER2-binding antibody domains and its innovative IgE platform technology. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiate...
1 Apr 2018 to 30 Jun 2020
IGEM-C is an IgE-based antibody targeting a melanoma antigen. The project involves the evaluation of a number of novel variants of the prototype for efficacy, manufacturability and stability. The antigen target for IGEM-C is found in many different solid tumours, and part of the project will be to develop animal models for these indications. The chosen va...
